{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:25:39Z","timestamp":1783747539638,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40264-023-01354-9","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T17:01:49Z","timestamp":1698771709000},"page":"1353-1362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National Databases"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-6823","authenticated-orcid":false,"given":"Johnmary T.","family":"Arinze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A. J.","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Vojinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"van Ballegooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuil","family":"Markov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rijnbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia M. C.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"1354_CR1","unstructured":"Morgan KA, Ahlawat R. Ranitidine. StatPearls [Internet]: Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"1354_CR2","unstructured":"H2 Receptor Blockers. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD); 2012."},{"issue":"2\u20133","key":"1354_CR3","first-page":"101","volume":"54","author":"CK Ching","year":"1995","unstructured":"Ching CK, Lam SK. Drug therapy of peptic ulcer disease. Br J Hosp Med. 1995;54(2\u20133):101\u20136.","journal-title":"Br J Hosp Med"},{"key":"1354_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.782536","volume":"8","author":"R Ruepp","year":"2021","unstructured":"Ruepp R, Fr\u00f6tschl R, Bream R, Filancia M, Girard T, Spinei A, et al. The EU response to the presence of nitrosamine impurities in medicines. Front Med (Lausanne). 2021;8: 782536.","journal-title":"Front Med (Lausanne)."},{"key":"1354_CR5","unstructured":"EMA. Suspension of ranitidine medicines in the EU. In: (CHMP) CfMPfHU, editor.: European Medicines Agency; 2020."},{"key":"1354_CR6","unstructured":"EMA. EMA confirms recommendation to suspend all ranitidine medicines in the EU. In: Agency EM, editor. Ranitidine Article 31 referrals: European Medicines Agency; 2020."},{"key":"1354_CR7","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574\u20138.","journal-title":"Stud Health Technol Inform."},{"key":"1354_CR8","unstructured":"WHO. Guidelines for ATC classification and DDD assignment 2013. 2012. http:\/\/www.whocc.no\/filearchive\/publications\/1_2013guidelines.pdf."},{"issue":"6912","key":"1354_CR9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/bmj.307.6912.1118","volume":"307","author":"H McGavock","year":"1993","unstructured":"McGavock H, Webb CH, Johnston GD, Milligan E. Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators. BMJ. 1993;307(6912):1118\u201320.","journal-title":"BMJ"},{"issue":"1","key":"1354_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0976-500X.124411","volume":"5","author":"BN Jhaveri","year":"2014","unstructured":"Jhaveri BN, Patel TK, Barvaliya MJ, Tripathi CB. Drug utilization pattern and pharmacoeconomic analysis in geriatric medical in-patients of a tertiary care hospital of India. J Pharmacol Pharmacother. 2014;5(1):15\u201320.","journal-title":"J Pharmacol Pharmacother"},{"issue":"8","key":"1354_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1365-2036.1998.00374.x","volume":"12","author":"L Martin","year":"1998","unstructured":"Martin L, Kerry H. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther. 1998;12(8):797\u2013805.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1354_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5639\/gabij.2018.0704.030","volume":"7","author":"B Godman","year":"2018","unstructured":"Godman B, Kurdi A, McCabe H, MacBride-Stewart S, Leporowski A, Hurding S, et al. Ongoing activities to influence the prescribing of proton pump inhibitors within the scottish national health service: their effect and implications. GaBI Journal. 2018;7(4):1\u201310.","journal-title":"GaBI Journal."},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"175628481877794","DOI":"10.1177\/1756284818777943","volume":"11","author":"\u00d3\u00d6 H\u00e1lfd\u00e1narson","year":"2018","unstructured":"H\u00e1lfd\u00e1narson \u00d3\u00d6, Potteg\u00e5rd A, Bj\u00f6rnsson ES, Lund SH, Ogmundsdottir MH, Steingr\u00edmsson E, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Ther Adv Gastroenterol. 2018;11:1756284818777943.","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"1354_CR14","doi-asserted-by":"publisher","first-page":"e001143","DOI":"10.1136\/fmch-2021-001143","volume":"9","author":"JS Frazer","year":"2021","unstructured":"Frazer JS, Frazer GR. Analysis of primary care prescription trends in England during the COVID-19 pandemic compared against a predictive model. Fam Med Community Health. 2021;9(3):e001143.","journal-title":"Fam Med Community Health."},{"issue":"10","key":"1354_CR15","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/s41416-021-01313-0","volume":"124","author":"JM Cox","year":"2021","unstructured":"Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt P, et al. The added value of H(2) antagonists in premedication regimens during paclitaxel treatment. Br J Cancer. 2021;124(10):1647\u201352.","journal-title":"Br J Cancer"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01354-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T16:27:56Z","timestamp":1701188876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01354-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01354-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"18 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the European Medicines Agency (EMA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors, Johnmary T. Arinze, Maria A.J. de Ridder, Dina Vojinovic, Hanne van Ballegooijen, Emanuil Marko, Talita Duarte-Salles, Peter Rijnbeek, and Katia M. C. Verhamme, declare no conflicts of interest directly relevant to the content of this article. This document expresses the opinion of the authors of the paper, and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study protocol was reviewed by the institutional review boards (IRBs) of the respective databases. Given the non-interventional and observational nature of the study, ethical approval was not required for LPD Belgium, DA Germany, and LPD France. Ethical approval was granted for this study by the Scientific Review Committee (21SRC063) of IMRD (UK), the IPCI Review Board (Registration no. 8\/2021) of IPCI Netherlands, and the Ethical Committee for Investigation of Medications (Code IEC: 21\/272-P) of SIDIAP Spain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was unnecessary as the study used only electronic health medical records, which had been de-identified prior to data access.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors collectively take responsibility for all aspects of the work, ensuring its accuracy and integrity, as well as participating in manuscript revisions and approving the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}